Actively Recruiting
Randomized Double-Blind Trial of Pumitamig Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients with Untreated Locally Recurrent or Metastatic Triple-Negative Breast Cancer Ineligible for PDL1 Therapy
Led by BioNTech SE · Updated on 2026-10-30
558
Participants Needed
224
Research Sites
39 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase III clinical trial to evaluate the effects and safety of pumitamig in patients with triple-negative breast cancer TNBC who have locally recurrent inoperable or metastatic disease and are ineligible for PDL1 therapy due to PD-L1 negative status. This trial compares pumitamig combined with chemotherapy to placebo combined with chemotherapy, using a randomized, double-blind design to measure progression-free survival and overall survival. Participants will be randomly assigned to one of two groups one receiving pumitamig plus a physicians choice of chemotherapy and the other receiving a placebo plus the same chemotherapy options. Chemotherapy regimens include paclitaxelnab-paclitaxel, gemcitabine plus carboplatin, or eribulin, administered by standard intravenous infusion. The treatment continues until disease progression, intolerable side effects, withdrawal, death, or trial end. After treatment, participants enter a safety follow-up period for up to 90 days and a survival follow-up phase lasting until death, withdrawal, loss of contact, or sponsor decision. During the study, participants undergo screening lasting up to 28 days before treatment begins. Assessments include tumor measurement using RECIST criteria, tissue sample collection excluding certain biopsy types, and performance status evaluation. Researchers track multiple outcome measures such as tumor response rates, quality of life scores, adverse events, and survival rates over periods up to approximately 49 months. This comprehensive monitoring ensures participant safety and collects data on the trial drugs impact compared to placebo with chemotherapy.
CONDITIONS
Brief Title
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Research Team
B
BioNTech clinical trials patient information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here